Biotechnology

Janux Therapeutics

Janux Therapeutics Stock Hits 52-Week Low but Reports Beat-Earnings

Oliver McCammon Maintains Buy Rating on Janux Therapeutics

Wedbush Reiterates Janux 'Outperform' Rating with Lowered Price Target to $45

Janux Therapeutics Inc. CCO Reports Disposal of Common Stock

US Bank Downgrades Janux Therapeutics Target Price to $49

Janux Therapeutics reports positive results from JANX007 trial in mCRPC patients

Janux Therapeutics to Host Virtual Presentation on Prostate Cancer Drug JANX007 Clinical Data

US Bank Securities Analyst Maintains Buy Rating for Janux Therapeutics

Janux Therapeutics released FY2025 9 Months Earnings on November 6, 2025 (EST), actual revenue USD 10M, actual EPS USD -1.3193

Janux Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 10 M (forecast USD 3.071 M), actual EPS USD -0.3919 (forecast USD -0.6194)

Analyst Maintains Buy Rating on Janux Therapeutics Inc

Janux Therapeutics released FY2025 Semi-Annual earnings on August 7 (EST), actual revenue USD 0, actual EPS USD -0.9275

Janux Therapeutics released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 272.73K), actual EPS USD -0.5469 (forecast USD -0.4709)

Janux Therapeutics Inc. Reports Q2 Net Loss Expansion

Janux Therapeutics Holding Virtual R&D Day

Janux Therapeutics shares fall, analysts give mixed ratings

Nationale Nederlanden Reduces Holdings in Janux Therapeutics

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Janux Therapeutics released FY2025 Q1 earnings on May 8 (EST), actual revenue USD 0 (forecast USD 650K), actual EPS USD -0.3804 (forecast USD -0.3862)

Janux Therapeutics Reports Increased Net Loss in Q1 2025, Launches Drug Studies

Mega Fortune

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Andersen

Inspirato

Medline Inc.

Creative Global Tech

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

ADMA生物制药

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制药

OpGen

福泰制药

再生元制药

Argenx

阿里拉姆制药

百济神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap